Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 65.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of iRhythm Holdings was 65.70% per year. The lowest was -44.60% per year. And the median was -2.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
iRhythm Holdings 5-Year EBITDA Growth Rate Related Terms
IRTC vs HAE, ITGR, LIVN: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, iRhythm Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRhythm Holdings 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where iRhythm Holdings's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 27.40% mean?
iRhythm Holdings (IRTC) has a 5-Year EBITDA Growth Rate of 27.40% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for iRhythm Holdings and its competitors.
Is iRhythm Holdings' 5-Year EBITDA Growth Rate too high?
iRhythm Holdings' current 5-Year EBITDA Growth Rate is 27.40%. Overall, iRhythm Holdings has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' 5-Year EBITDA Growth Rate compare to HAE and ITGR?
iRhythm Holdings' 5-Year EBITDA Growth Rate of 27.40% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for iRhythm Holdings and its competitors. iRhythm Holdings's current 5-Year EBITDA Growth Rate is 27.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (IRTC) is currently considered Modestly Undervalued. The stock's GF Value™ is $154.41, compared to a current price of $127.84 — trading 17.2% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 27.40%. iRhythm Holdings' overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For iRhythm Holdings (IRTC), the current 5-Year EBITDA Growth Rate is 27.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRhythm Holdings (IRTC) Overvalued in 2026?
Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued.
The current stock price of $127.84 is trading 17.2% below its estimated GF Value™ of $154.41.
GuruFocus considers iRhythm Holdings to be Modestly Undervalued.
Key valuation signals for IRTC:
5-Year EBITDA Growth Rate: 27.40%
GF Value™: $154.41 vs. price of $127.84 (17.2% below fair value)
No single metric tells the full story. See the IRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
79GF Score
Get the complete analysis for IRTC
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRTC has been successfully added to your 
